• Users Online: 1137
  • Home
  • Print this page
  • Email this page
ARTICLE
Year : 2015  |  Volume : 4  |  Issue : 5  |  Page : 63

Primary immunodeficiency leading to mycobacterial disease


Department of Infectious Diseases, Leiden University Medical Center, Leiden, The Netherlands

Correspondence Address:
Esther van de Vosse
Department of Infectious Diseases, Leiden University Medical Center, Leiden
The Netherlands
Login to access the Email id

Source of Support: None, Conflict of Interest: None


Rights and PermissionsRights and Permissions

More than 150 different mycobacterial strains are known, of which only a few are considered pathogens in humans. The most pathogenic strains are the mycobacteria from the Mycobacterium tuberculosis complex which cause the globally spread disease tuberculosis and the Mycobacterium leprae and Mycobacterium lepromatosis strains that cause leprosy. In addition to these well-known mycobacteria, there are many non-tuberculous mycobacteria (NTM) that are present in the environment and that seldom cause severe disease in healthy individuals. NTM infection can lead to severe disease in individuals with a failing immune system due to a primary or secondary immunodeficiency. Mendelian susceptibility to mycobacterial disease (MSMD) is a rare primary immunodeficiency characterized by a predisposition to severe, sometimes lethal disease caused by otherwise poorly virulent NTM, as well as the vaccine strain Mycobacterium bovis BCG. In these patients the mycobacterial infection is often disseminated to various parts of the body and is difficult to treat. Interestingly, MSMD patients do not, in general, develop pulmonary tuberculosis. MSMD is usually caused by mutations in genes involved in the IL-12/IFN-γ pathway, such as: IL12RB1 which encodes the IL-12Rβ1 chain of the IL-12 and the IL-23 receptor, IL12B which encodes the IL-12p40 subunit of IL-12 and IL-23, IFNGR1 and IFNGR2 which encode the two chains of the IFN-γ receptor, and STAT1 which encodes one of the proteins that signal in response to IFN-γ. The aim of our research is to identify the immunological and genetic defects in MSMD patients. Hereto the integrity of the IL-12/IFN-γ pathway is analysed in blood and isolated cells from the patients, as well as expression of receptor chains on the membrane of the cells. Mutations are subsequently identified by sequencing the genes involved. The effect of novel mutations that lead to amino acid changes can be analysed in retroviral expression models, as we have done for amongst others IL12RB1, IFNGR1 and IFNGR2. To facilitate the analysis of variations identified by researchers around the world, databases have been set up that contain all reported MSMD patients and mutations (see for instance: www.lovd.nl/IL12RB1). Thus far, just over 400 patients have been reported worldwide with MSMD and this is probably only the tip of the iceberg. Also, other genes are still expected to be found to cause MSMD; no genes have been reported so far in which mutations specifically lead to susceptibility to tuberculosis.


[PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed313    
    Printed4    
    Emailed0    
    PDF Downloaded26    
    Comments [Add]    

Recommend this journal